Your browser doesn't support javascript.
loading
Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.
Meysman, Pieter; De Neuter, Nicolas; Bartholomeus, Esther; Elias, George; Van den Bergh, Johan; Emonds, Marie-Paule; Haasnoot, Geert W; Heynderickx, Steven; Wens, Johan; Michels, Nele R; Lambert, Julien; Lion, Eva; Claas, Frans H J; Goossens, Herman; Smits, Evelien; Van Damme, Pierre; Van Tendeloo, Viggo; Beutels, Philippe; Suls, Arvid; Mortier, Geert; Laukens, Kris; Ogunjimi, Benson.
  • Meysman P; ADREM Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2020, Antwerp, Belgium. pieter.meysman@uantwerpen.be.
  • De Neuter N; Biomedical Informatics Research Network Antwerp (biomina), University of Antwerp, 2020, Antwerp, Belgium. pieter.meysman@uantwerpen.be.
  • Bartholomeus E; Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium. pieter.meysman@uantwerpen.be.
  • Elias G; ADREM Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2020, Antwerp, Belgium.
  • Van den Bergh J; Biomedical Informatics Research Network Antwerp (biomina), University of Antwerp, 2020, Antwerp, Belgium.
  • Emonds MP; Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
  • Haasnoot GW; Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
  • Heynderickx S; Center for Medical Genetics, Antwerp University Hospital, 2650, Edegem, Belgium.
  • Wens J; Center for Medical Genetics, University of Antwerp, 2650, Edegem, Belgium.
  • Michels NR; Antwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, 2020, Antwerp, Belgium.
  • Lambert J; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650, Antwerp, Belgium.
  • Lion E; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, 2650, Edegem, Belgium.
  • Claas FHJ; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650, Antwerp, Belgium.
  • Goossens H; Laboratory for Histocompatibility and Immunogenetics (HILA), Red Cross Flanders, 2800, Mechelen, Belgium.
  • Smits E; Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, 2300, Leiden, The Netherlands.
  • Van Damme P; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650, Antwerp, Belgium.
  • Van Tendeloo V; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, 2650, Edegem, Belgium.
  • Beutels P; Department of Primary and Interdisciplinary Care, University of Antwerp, 2610, Wilrijk, Belgium.
  • Suls A; Department of Primary and Interdisciplinary Care, University of Antwerp, 2610, Wilrijk, Belgium.
  • Mortier G; Department of Dermatology, Antwerp University Hospital/University of Antwerp, 2650, Edegem, Belgium.
  • Laukens K; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, 2650, Antwerp, Belgium.
  • Ogunjimi B; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, 2650, Edegem, Belgium.
Immunogenetics ; 70(6): 363-372, 2018 06.
Article en En | MEDLINE | ID: mdl-29196796
ABSTRACT
Around 30% of individuals will develop herpes zoster (HZ), caused by the varicella zoster virus (VZV), during their life. While several risk factors for HZ, such as immunosuppressive therapy, are well known, the genetic and molecular components that determine the risk of otherwise healthy individuals to develop HZ are still poorly understood. We created a computational model for the Human Leukocyte Antigen (HLA-A, -B, and -C) presentation capacity of peptides derived from the VZV Immediate Early 62 (IE62) protein. This model could then be applied to a HZ cohort with known HLA molecules. We found that HLA-A molecules with poor VZV IE62 presentation capabilities were more common in a cohort of 50 individuals with a history of HZ compared to a nationwide control group, which equated to a HZ risk increase of 60%. This tendency was most pronounced for cases of HZ at a young age, where other risk factors are less prevalent. These findings provide new molecular insights into the development of HZ and reveal a genetic predisposition in those individuals most at risk to develop HZ.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígenos HLA-A / Transactivadores / Proteínas del Envoltorio Viral / Proteínas Inmediatas-Precoces / Herpesvirus Humano 3 / Herpes Zóster Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígenos HLA-A / Transactivadores / Proteínas del Envoltorio Viral / Proteínas Inmediatas-Precoces / Herpesvirus Humano 3 / Herpes Zóster Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2018 Tipo del documento: Article